Literature DB >> 35022897

USP8 inhibitor-induced DNA damage activates cell cycle arrest, apoptosis, and autophagy in esophageal squamous cell carcinoma.

Beibei Sha1, Yaxin Sun1, Shan Zhao1, Miaomiao Li1, Wenjing Huang1, Zheng Li2, Jianxiang Shi3, Xuefei Han1, Pei Li1, Tao Hu4, Ping Chen5,6.   

Abstract

Increasing evidence suggests that targeting ubiquitin-specific peptidase 8 (USP8) serves as an attractive anti-cancer strategy. However, the role of USP8 inhibitor, DUB-IN-1, in esophageal squamous cell carcinoma (ESCC) cells still needs to be explored. Here, immunohistochemistry was employed to examine the expression of USP8 in ESCC tissues. Cell Counting Kit-8 (CCK-8) was used to evaluate cell proliferation ability, and propidium iodide (PI) was selected to test the effect of DUB-IN-1 on cell cycle. AnnexinV-FITC/PI staining and the activity of caspase 3 were detedcted to evaluate apoptosis. Transmission electron microscope, microtubule-associated protein 1 light-chain 3 (LC3) expression, and acridine orange (AO) staining were selected to check if there was autophagy. Comet assay and γ-H2AX immunofluorescence was used to monitor DNA damage. Rescue experiment was used to determine the key role of of p53 in cell cycle, apoptosis, and autophagy. Results revealed that the leve of USP8 was higher in ESCC tissues than that in tissues adjacent to carcinoma. DUB-IN-1, an USP8 inhibitor, caused DNA damage, led to G2/M phase block by p53-p21 axis, and triggered apoptosis by regulating the p53 target proteins including Bax, Noxa, and Puma. Besides, DUB-IN-1 could stimulate autophagy through p53-dependent adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) activation. Taken together, this study revealed the cytotoxic effects and the mechanism of DUB-IN-1, which indicated that DUB-IN-1 may be a novel inhibitor targeting USP8 that can kill ESCC cells. USP8 inhibitor, DUB-IN-1, treatment could inhibit esophageal squamous cell carcinoma cell growth and induce G2/M cell cycle arrest, apoptosis, and autophagy by DNA damage-induced p53 activation. DUB-IN-1 treatment led to G2/M cell cycle arrest by upregulating the protein level of p21 and triggered apoptosis by modulating the p53 target proteins including Bax, Noxa, and Puma. Meanwhile, DUB-IN-1 treatment stimulated protective autophagy through p53-dependent AMPK activation. Collectively, these findings suggested that DNA damage-triggered p53 activation, p53-Puma/Noxa/Bax, p53-p21, and p53-AMPK pathways were all involved in the effect of DUB-IN-1.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Apoptosis; Autophagy; DNA damage; Esophageal squamous cell carcinoma; USP8 inhibitor

Year:  2022        PMID: 35022897     DOI: 10.1007/s10565-021-09686-x

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  53 in total

1.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage.

Authors:  F Bunz; A Dutriaux; C Lengauer; T Waldman; S Zhou; J P Brown; J M Sedivy; K W Kinzler; B Vogelstein
Journal:  Science       Date:  1998-11-20       Impact factor: 47.728

2.  Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes.

Authors:  Matteo Colombo; Stefania Vallese; Ilaria Peretto; Xavier Jacq; Jean-Christophe Rain; Frédéric Colland; Philippe Guedat
Journal:  ChemMedChem       Date:  2010-04-06       Impact factor: 3.466

3.  USP8 is a novel target for overcoming gefitinib resistance in lung cancer.

Authors:  Sanguine Byun; Sung-Young Lee; Jihoon Lee; Chul-Ho Jeong; Lee Farrand; Semi Lim; Kanamata Reddy; Ji Young Kim; Mee-Hyun Lee; Hyong Joo Lee; Ann M Bode; Ki Won Lee; Zigang Dong
Journal:  Clin Cancer Res       Date:  2013-06-07       Impact factor: 12.531

Review 4.  p21 in cancer: intricate networks and multiple activities.

Authors:  Tarek Abbas; Anindya Dutta
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

5.  Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.

Authors:  Mikhail Burmakin; Yao Shi; Elisabeth Hedström; Per Kogner; Galina Selivanova
Journal:  Clin Cancer Res       Date:  2013-07-17       Impact factor: 12.531

6.  Ochratoxin A induces G(2) phase arrest in human gastric epithelium GES-1 cells in vitro.

Authors:  Jinfeng Cui; Lingxiao Xing; Zengning Li; Sha Wu; Juan Wang; Jing Liu; Junling Wang; Xia Yan; Xianghong Zhang
Journal:  Toxicol Lett       Date:  2010-01-07       Impact factor: 4.372

7.  Clinical and prognostic importance of XIAP and USP8 in advanced stages of non-small cell lung cancer.

Authors:  M Baykara; M Yaman; S Buyukberber; G Tufan; U Demirci; M Benekli; U Coskun; A Ozet; E Umit Bagriacik
Journal:  J BUON       Date:  2013 Oct-Dec       Impact factor: 2.533

8.  USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.

Authors:  Angelo Agathanggelou; Edward Smith; Nicholas J Davies; Marwan Kwok; Anastasia Zlatanou; Ceri E Oldreive; Jingwen Mao; David Da Costa; Sina Yadollahi; Tracey Perry; Pamela Kearns; Anna Skowronska; Elliot Yates; Helen Parry; Peter Hillmen; Celine Reverdy; Remi Delansorne; Shankara Paneesha; Guy Pratt; Paul Moss; A Malcolm R Taylor; Grant S Stewart; Tatjana Stankovic
Journal:  Blood       Date:  2017-05-11       Impact factor: 22.113

9.  p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling.

Authors:  Andrei V Budanov; Michael Karin
Journal:  Cell       Date:  2008-08-08       Impact factor: 41.582

10.  USP8 is a Novel Therapeutic Target in Melanoma Through Regulating Receptor Tyrosine Kinase Levels.

Authors:  Baoxue Duan; Changying Wang; Zeng Liu; Xiaoyu Yang
Journal:  Cancer Manag Res       Date:  2021-05-24       Impact factor: 3.989

View more
  2 in total

Review 1.  Research Progress of DUB Enzyme in Hepatocellular Carcinoma.

Authors:  Jie Zhao; Jinhui Guo; Yanan Wang; Qiancheng Ma; Yu Shi; Feng Cheng; Qiliang Lu; Wen Fu; Guangxiong Ouyang; Ji Zhang; Qiuran Xu; Xiaoge Hu
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

2.  Antisense lncRNA PCNA-AS1 promotes esophageal squamous cell carcinoma progression through the miR-2467-3p/PCNA axis.

Authors:  Tao Hu; Yunfeng Niu; Jianfeng Fu; Zhiming Dong; Dongwei He; Junfeng Liu
Journal:  Open Med (Wars)       Date:  2022-09-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.